The Patent Finder

Dart Neuroscience, LLC

26 patents currently held · Updated Nov 17, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Feb 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 26, 2026
    The maintenance fee for Substituted pyridine and pyrazine compounds as PDE4 inhibitors (US 9,040,692) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
  • 1 fee due Dec 27, 2026
    The maintenance fee for Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors (US 11,685,745) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones (US 10,376,514) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 1 fee due Mar 1, 2027
    The maintenance fee for Substituted pyridine and pyrazine compounds as PDE4 inhibitors (US 9,120,770) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
  • 1 fee due May 3, 2027
    The maintenance fee for Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones (US 9,175,010) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 1 fee due Jun 10, 2027
    The maintenance fee for Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl Compounds as PDE2 Inhibitors (US 10,501,465) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
  • 1 fee due Sep 15, 2027
    The maintenance fee for Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders (US 9,284,335) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
  • 1 fee due Oct 2, 2027
    The maintenance fee for Substituted cyclohexyl compounds as NOP inhibitors (US 11,945,808) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 19, 2026
  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,338,405Therapeutic piperazines
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,029,397Therapeutic isoxazole compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,284,335Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,499,562Substituted Thiophene- and Furan-Fused AZOLOPYRIMIDINE-5-(6H)-ONE Compounds
In force
 · Medium confidence
In forceMedium confidence
US 9,533,996Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,105,367Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,376,514Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,175,010Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,279,691Substituted pyridine and pyrazine compounds as PDE4 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,040,692Substituted pyridine and pyrazine compounds as PDE4 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 26 patents shown.
Pro members see all 26.
Pro members: see all 26 patents
Also on record, not counted in the 26: 2 patents in force now held by others · 34 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 abandoned · 5 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited